Abstract
There is a clear need for new antibiotics to improve the efficacy of long-term antimicrobial therapy in pwCF. Cefiderocol is currently licensed for the treatment of infections due to Gram-negative organisms with limited treatment options. The aim of this study was to determine the susceptibility of a broad range of CF Gram-negative pathogens to cefiderocol and relevant comparator antibiotics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
